News: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

87.70EUR
11:36am EST
Change (% chg)

€0.16 (+0.18%)
Prev Close
€87.54
Open
€87.37
Day's High
€87.70
Day's Low
€86.58
Volume
3,892,847
Avg. Vol
3,416,479
52-wk High
€89.95
52-wk Low
€69.58

Search Stocks
Select another date:
Photo

Sacked Sanofi boss joins PureTech board

PARIS - Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company.

CORRECTED-Sacked Sanofi boss joins PureTech board

PARIS, Feb 27 - Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company.

Sanofi diabetes drug Toujeo wins EU green light, pricing in focus

LONDON - French drugmaker Sanofi's new Toujeo diabetes drug has been recommended for approval in Europe, two days after being cleared for sale in the United States, regulators said on Friday.

UPDATE 1-Sanofi diabetes drug Toujeo wins EU green light, pricing in focus

* Pricing seen key in determining Toujeo take-up (Adds product details, debate on pricing)

Sanofi diabetes drug Toujeo wins European green light

LONDON, Feb 27 - French drugmaker Sanofi's new Toujeo diabetes drug has been recommended for approval in Europe, two days after being cleared to go on sale in the United States, regulators said on Friday.

Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

- French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult.

UPDATE 2-Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

Feb 26 - French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult.

Sanofi diabetes drug awaits imminent EU green light

LONDON - Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday.

Sanofi diabetes drug awaits imminent EU green light

LONDON, Feb 26 - Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday.

FDA approves Sanofi's diabetes drug Toujeo

- U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus.

Select another date:
Search Stocks